Active substance
Rocuronium
- SFDA 4
- US FDA 25
- Health Canada 6
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ESMERON 10MG\ML VIAL | 10 mg/ml | Solution for injection · Intravenous use | 10 Vial | SAR 215.05 | NCE · Prescription | Merck Sharp & Dohme B.V | Valid |
| LAXIRA | 10 mg/ml | Solution for injection · Intravenous use | 10 Ampoule | SAR 182.80 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| RUCORON 50MG\5ML SOLUTION FOR IV BOLUS OR INFUSION | 10 mg/ml | Solution for injection · Intravenous use | 10 Vial | SAR 182.80 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Rocuronium Bromide BOS | 10 mg/ml | Solution for injection · Intravenous use | 10 Vial | SAR 127.95 | Generic · Prescription | Boston Oncology Arabia | Valid |
Indications — CHI Daman Drug Formulary
ANESTHESIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | HOSPIRA | Prescription | 26 Nov 2008 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | MYLAN INSTITUTIONAL | Prescription | 26 Nov 2008 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | SANDOZ | Prescription | 5 Dec 2008 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | FRESENIUS KABI USA | Prescription | 29 Dec 2008 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | SAGENT PHARMS INC | Prescription | 28 Jul 2010 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | TAMARANG | Prescription | 27 Aug 2012 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | WEST WARD PHARM CORP | Prescription | 28 Feb 2017 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | EUGIA PHARMA | Prescription | 12 Apr 2017 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | GLAND | Prescription | 4 Apr 2018 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | PIRAMAL CRITICAL | Prescription | 13 Aug 2019 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | PRINSTON INC | Prescription | 26 May 2022 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | CAPLIN | Prescription | 2 Mar 2023 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | MEITHEAL | Prescription | 8 May 2023 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | SHANDONG | Prescription | 12 Jul 2024 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML) | injectable · injection | STERISCIENCE | Prescription | 22 Jul 2024 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | MANKIND PHARMA | Prescription | 29 May 2025 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | solution · intravenous | FRESENIUS KABI USA | Prescription | 9 Jun 2025 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML) | solution · intravenous | B BRAUN MEDICAL | Prescription | 24 Oct 2025 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | ASPIRO | Prescription | 4 Mar 2026 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | BAXTER HLTHCARE CORP | Prescription | 18 Sep 2026 |
| ZEMURON | 50MG/5ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 10MG/ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 100MG/10ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | ORGANON USA INC | Discontinued | 17 Mar 1994 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | TEVA PHARMS | Discontinued | 26 Nov 2008 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML) | injectable · injection | HIKMA | Discontinued | 24 May 2023 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | RISING | Discontinued | 12 Jul 2024 |
| ROCURONIUM BROMIDE | 50MG/5ML (10MG/ML); 100MG/10ML (10MG/ML) | injectable · injection | KNACK | Discontinued | 6 Jan 2026 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| EUGIA-ROCURONIUM BROMIDE INJECTION | 02498820 | 10 MG / ML | SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| ROCURONIUM BROMIDE INJECTION | 02318415 | 10 MG / ML | SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| ROCURONIUM BROMIDE INJECTION | 02469774 | 10 MG / ML | SOLUTION · INTRAVENOUS | JUNO PHARMA CANADA INC. |
| ROCURONIUM BROMIDE INJECTION | 02517744 | 10 MG / ML | SOLUTION · INTRAVENOUS | HIKMA CANADA LIMITED |
| ROCURONIUM BROMIDE INJECTION | 02528657 | 10 MG / ML | SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| ROCURONIUM BROMIDE INJECTION | 02529831 | 10 MG / ML | SOLUTION · INTRAVENOUS | JAMP PHARMA CORPORATION |
Safety signals and safety-related labeling changes
- US FDA 26 Jul 2018 ZEMURON — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.